Trial Profile

An Open-Label Extension Study of ISIS 721744 in Patients With Hereditary Angioedema

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2025 According to Ionis Pharmaceuticals Media Release,based on positive results from the Phase 3 OASIS-HAE and OASISplus studies,the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of DAWNZER (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema in adults and adolescents (>12 years).The positive opinion is now referred to the European Commission for an approval decision, expected in Q1 2026.
06 Nov 2025 According to Ionis Pharmaceuticals Media Release, data from this study to be presented at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Orlando, Florida.
06 Nov 2025 Results published in the Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com